Tarsus Pharmaceuticals Outlines Transformative Plans for 2025

Tarsus Pharmaceuticals, Inc. TARS has revealed its five-year development plan centered on the progression of TP-04 for ocular rosacea, which is untreated despite affecting millions of adults globally, as well as maintaining the expansion of XDEMVY, the company’s first-line drug for Demodex blepharitis (DB). XEDEMVY reported more than $113 million in net sales for the first nine months of 2024, and Tarsus continues to gain significant traction with physicians. Tarsus intends to boost its commercial activities, such as its first direct-consumer advertising campaign in 2025. In regards to ocular rosacea, Tarsus plans to start a Phase 2 study of TP-04, a potential new treatment, in the second half of the year 2025.

The company is also investing in international markets, with the regulatory sessions in Europe, Japan, and China in progress at the time of the report. Furthermore, Tarsus will also provide an update on TP-05 targeting Lyme disease prevention in its FY 2024 financial year earnings call teleconference „2025 is set to be a transformative year for Tarsus as the company consolidates pipeline, ramps up on XDEMVY and develops new therapies,” said Bobak Azamian, Chief executive Officer, Tarsus. Its endeavors reveal the firm’s desire to meet unexplored demand in ophthalmology and other sectors.